Health Condition 1: null- Patients with multiple myeloma post autologous hematopoeitic stem cell transplatation
Conditions
Interventions
Intervention1: Bortezomib
Lenalidomide
Dexamethasone: 1.Inj. Bortezomib 2 mg s/c (to be diluted in 1.5 ml normal saline) weekly doses (d1,d8,d15,d22)
2.Cap. Lenalidomide 15mg Per Oral daily for 15 da
Sponsors
All India Institute of Medical Sciences
Eligibility
Inclusion criteria
Inclusion criteria: All multiple myeloma patients who have undergone Autologous Hematopoietic stem cell transplant will be enrolled at 100 days (± 2weeks) of post ASCT
Exclusion criteria
Exclusion criteria: 1. ECOG Performance status 3 and 4 2. Uncontrolled diabetes and hypertension 3. peripheral neuropathy > grade 2 4. Any contraindication to anticoagulant prophylaxis 5. Persistent cytopenias >=1 cell line (Hb
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess response rate after post Autologous Hematopoietic Stem ceell transplantation consolidation therapyTimepoint: 1ST August, 2016 to 31st May, 2018 | — |
Secondary
| Measure | Time frame |
|---|---|
| 1.To assess for MRD negativity rate post consolidation therapy 2.To assess for one year PFS 3.To assess for toxicity of consolidation therapy Timepoint: 1ST August, 2016 to 31st May, 2018 | — |
Countries
India
Contacts
Public ContactDr Patekar Mukesh Bhimrao
All India Institute of Medical Sciences
Outcome results
None listed